Denver—Can you define extrapolation, or explain the FDA process for approval of interchangeability? Experts say you should be able to, as an increasing number of biosimilar drugs are entering the marketplace and providers are not adequately informed about these agents.
“As pharmacists, we are uniquely positioned to educate clinicians as well as patients about biosimilars, and to answer their questions,” Jennifer Day, PharmD, a pharmacist project manager at Kaiser Permanente